Key TakeawaysNovavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results.The company has cut its guidance multiple times this year, and the new range is below the analyst consensus.On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.  The COVID-19 and flu vacci ...